Base de dados : MEDLINE
Pesquisa : C10.228.140.617.738 [Categoria DeCS]
Referências encontradas : 3290 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 329 ir para página                         

  1 / 3290 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470359
[Au] Autor:Topuz MF; Sari M; Binnetoglu A; Dogrul R; Bugdayci O; Seker A
[Ad] Endereço:Department of Otorhinolaryngology, Dumlupinar University School of Medicine, Istiklal Parish Okmeydani st. No: 10 Merkez, Kütahya, Turkey. drfatihtopuz@yahoo.com.
[Ti] Título:Is endoscopic endonasal transsphenoidal surgery increases the susceptibility to rhinosinusitis.
[So] Source:Eur Arch Otorhinolaryngol;274(8):3065-3069, 2017 Aug.
[Is] ISSN:1434-4726
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The aim of the study was to analyze whether the measurement of changes in the anatomical position and volume of middle concha, the volume changes in the area between the middle concha and lamina papyracea, the evaluation of opacification in major paranasal sinuses, and osteomeatal complex occlusion in cases with middle concha by out-fracture technique during endoscopic endonasal transsphenoidal approach is a minimally invasive surgery, and also to find out whether these changes lead to the development of tendency to rhinosinusitis. It was a retrospective clinical study. Forty-five cases, between 2013 and 2015, planned for endoscopic endonasal transsphenoidal surgery due to hypophyseal pathology at the Neurosurgery Departments of Marmara University Hospital were evaluated retrospectively. The patients were evaluated for the changes in the anatomy of the middle concha and the effects of these changes to paranasal sinuses by paranasal computed tomographies were studied at the preoperative second week and postoperative 12 month. The Lund-Mackay scoring system was used for the evaluation of opacification in the five major paranasal sinuses and occlusion of the osteomeatal complex in the pre- and postoperative period. The Lund-Mackay scoring system was used to analyze the paranasal computed tomography of the patients at the preoperative 2 weeks and postoperative first year. According to the Lund-Mackay scoring system, no significant difference was detected between the preoperative and postoperative opacification of paranasal sinuses (p > 0.05). Besides, there was also no significant difference between the preoperative and postoperative osteomeatal complex occlusion (p > 0.05). Considering the distance between middle concha and lamina papyracea following the out-fracture of the middle concha, a significant lateralization of 0.5 mm between the preoperative and postoperative period was observed (p < 0.05). In addition, a significant change was also detected in the volume of middle concha (p < 0.05). The volume of the area between the middle concha and lamina papyracea was decreased with a statistical significance (p < 0.05). The endoscopic endonasal transsphenoidal surgery causes some variations in the structures of the middle concha, paranasal sinuses, and OMC, but these changes do not lead to significant rhinologic pathologies.
[Mh] Termos MeSH primário: Cirurgia Endoscópica por Orifício Natural
Rinite/etiologia
Sinusite/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Suscetibilidade a Doenças
Feminino
Seres Humanos
Masculino
Meia-Idade
Cirurgia Endoscópica por Orifício Natural/efeitos adversos
Nariz
Seios Paranasais/diagnóstico por imagem
Doenças da Hipófise/cirurgia
Estudos Retrospectivos
Osso Esfenoide
Conchas Nasais/diagnóstico por imagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1007/s00405-017-4598-4


  2 / 3290 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480822
[Au] Autor:Zhang Q; Zang L; Li YJ; Han BY; Gu WJ; Yan WH; Jin N; Chen K; Du J; Wang XL; Guo QH; Yang GQ; Yang LJ; Ba JM; Lv ZH; Dou JT; Lu JM; Mu YM
[Ad] Endereço:Department of Endocrinology, Chinese PLA General Hospital.
[Ti] Título:Thyrotrophic status in patients with pituitary stalk interruption syndrome.
[So] Source:Medicine (Baltimore);97(2):e9084, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pituitary stalk interruption syndrome (PSIS) is associated with simultaneous or subsequent pituitary hormone deficiencies (PHDs). Although the clinical features of multiple PHDs are well known, the status of the thyrotrophic axis in PSIS has not been thoroughly investigated.The clinical data of 89 PSIS patients and 34 Sheehan syndrome (SS) patients were retrospectively analyzed.The prevalence of central hypothyroidism in the PSIS patients and the SS patients was 79.8% and 70.6%, respectively. The thyroid-stimulating hormone (TSH) levels in the PSIS patients were significantly higher in comparison with the SS patients (5.13 ±â€Š3.40 vs 1.67 ±â€Š1.20 mU/L, P < .05). TSH elevation (8.79 ±â€Š3.17 mU/L) was noticed in 29 of 71 (40.85%) hypothyroid PSIS patients but not in the 24 hypothyroid SS patients. The TSH levels in the hypothyroid PSIS patients were significantly higher in comparison with the euthyroid PSIS patients (5.42 ±â€Š3.67 vs 3.66 ±â€Š1.50 mU/L). Thyroid hormone replacement significantly reduced the TSH levels in the PSIS patients with elevated TSH levels from 7.24 ±â€Š0.98 to 1.67 ±â€Š1.51 mU/L (P < .05). The logistic regression analysis suggested that TSH level was not significantly associated with pituitary stalk status and height of the anterior pituitary gland.PSIS is a newly recognized cause of central hypothyroidism. The proportion and amplitude of TSH elevations are higher in PSIS than in other causes of central hypothyroidism.
[Mh] Termos MeSH primário: Doenças da Hipófise/metabolismo
Tireotropina/metabolismo
[Mh] Termos MeSH secundário: Adulto
Feminino
Terapia de Reposição Hormonal
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
Doenças da Hipófise/diagnóstico por imagem
Doenças da Hipófise/tratamento farmacológico
Doenças da Hipófise/epidemiologia
Hipófise/diagnóstico por imagem
Hipófise/efeitos dos fármacos
Hipófise/metabolismo
Prevalência
Estudos Retrospectivos
Tireotropina/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9002-71-5 (Thyrotropin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009084


  3 / 3290 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29190133
[Au] Autor:Ajmal A; Auchus RJ
[Ti] Título:BUILDING A BRIDGE IN LONDON, FOR MY CAREER AND MY ADOLESCENT PITUITARY PATIENTS.
[So] Source:Endocr Pract;23(11):1354-1356, 2017 Nov.
[Is] ISSN:1530-891X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças da Hipófise/terapia
[Mh] Termos MeSH secundário: Adolescente
Endocrinologia/educação
Seres Humanos
Doenças da Hipófise/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.4158/EP-2017-0054


  4 / 3290 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334271
[Au] Autor:Corona G; Rastrelli G; Reisman Y; Sforza A; Maggi M
[Ad] Endereço:a Endocrinology Unit, Medical Department , Maggiore-Bellaria Hospital, Azienda-Usl Bologna , Bologna , Italy.
[Ti] Título:The safety of available treatments of male hypogonadism in organic and functional hypogonadism.
[So] Source:Expert Opin Drug Saf;17(3):277-292, 2018 Mar.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In the case of primary male hypogonadism (HG), only testosterone (T) replacement therapy (TRT) is possible whereas when the problem is secondary to a pituitary or hypothalamus alteration both T production and fertility can be, theoretically, restored. We here systematically reviewed and discussed the advantages and limits of medications formally approved for the treatment of HG. Areas covered: Data derived from available meta-analyses of placebo controlled randomized trials (RCTs) were considered and analyzed. Gonadotropins are well-toleratedand their use is mainly limited by higher costs and a more cumbersome treatment schedule than TRT. Available RCTs on TRT suggest that cardiovascular (CV) and venous thromboembolism risk is not a major issue and that prostate safety is guaranteed. The risk of increased hematocrit is mainly limited to the use of short terminjectable preparations. Expert opinion: In the last few years the concept of 'organic' irreversible HG and 'functional' or age- and comorbidity-related HG has been introduced. This definition is not evidence-based. The majority of RCTs enrolled patients with 'functional' HG. Considering the significant improvement in body composition, glucose metabolism and sexual activity, TRT should not be limited to 'organic' HG, but also offered for 'functional'.
[Mh] Termos MeSH primário: Gonadotropinas/administração & dosagem
Hipogonadismo/tratamento farmacológico
Testosterona/administração & dosagem
[Mh] Termos MeSH secundário: Gonadotropinas/efeitos adversos
Terapia de Reposição Hormonal/efeitos adversos
Terapia de Reposição Hormonal/métodos
Seres Humanos
Hipogonadismo/etiologia
Doenças Hipotalâmicas/complicações
Infertilidade Masculina/tratamento farmacológico
Infertilidade Masculina/etiologia
Masculino
Doenças da Hipófise/complicações
Ensaios Clínicos Controlados Aleatórios como Assunto
Testosterona/efeitos adversos
Testosterona/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadotropins); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180116
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2018.1424831


  5 / 3290 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28871578
[Au] Autor:Seki T; Yasuda A; Oki M; Kitajima N; Takagi A; Nakajima N; Miyajima A; Fukagawa M
[Ad] Endereço:Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Iseharashi, Kanagawa 259-1193, Japan. tsekimdpdd@tokai-u.jp.
[Ti] Título:Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.
[So] Source:Tokai J Exp Clin Med;42(3):115-120, 2017 Sep 20.
[Is] ISSN:2185-2243
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Currently, nivolumab (an anti-programmed cell death-1 receptor monoclonal antibody) is available for many types of advanced cancers in Japan. However, there have been few detailed case reports about endocrine-related adverse events of this therapy. Here, we report a patient with metastatic renal cell carcinoma who presented with secondary adrenal insufficiency following nivolumab therapy. Endocrinological assessment by rapid adrenocorticotropic hormone (ACTH) and corticotropin-releasing hormone (CRH) tests revealed that the patient's disorder was a secondary adrenal insufficiency due to pituitary dysfunction. Moreover, the results of the thyrotropin-releasing hormone (TRH), luteinizing hormone-releasing hormone (LH-RH) and growth hormone-releasing peptide-2 (GHRP-2) tests showed that only the ACTH function was destroyed (isolated ACTH deficiency). The magnetic resonance imaging (MRI) findings of hypophysitis, which is the major cause of isolated ACTH deficiency, usually demonstrate enlargement of the pituitary gland. However, the MRI findings of our case showed no abnormalities of the pituitary gland and stalk. Therefore, not only oncologists, but also other specialists, including doctors in emergency units, should have knowledge of this specific feature. Our clinical observation could be useful to avoid a delay in diagnosis and to treat life-threatening adverse effects of nivolumab therapy, such as secondary adrenal insufficiency.
[Mh] Termos MeSH primário: Insuficiência Adrenal/induzido quimicamente
Anticorpos Monoclonais/efeitos adversos
Antineoplásicos/efeitos adversos
Carcinoma de Células Renais/tratamento farmacológico
Neoplasias Renais/tratamento farmacológico
[Mh] Termos MeSH secundário: Insuficiência Adrenal/diagnóstico
Hormônio Adrenocorticotrópico/sangue
Idoso
Anticorpos Monoclonais/administração & dosagem
Antineoplásicos/administração & dosagem
Biomarcadores/sangue
Carcinoma de Células Renais/secundário
Hormônio Liberador da Corticotropina/sangue
Feminino
Seres Humanos
Hiponatremia/induzido quimicamente
Hipofisite/complicações
Hipofisite/diagnóstico por imagem
Infusões Intravenosas
Neoplasias Renais/secundário
Imagem por Ressonância Magnética
Doenças da Hipófise/complicações
Doenças da Hipófise/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 0 (Biomarkers); 31YO63LBSN (nivolumab); 9002-60-2 (Adrenocorticotropic Hormone); 9015-71-8 (Corticotropin-Releasing Hormone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE


  6 / 3290 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28693060
[Au] Autor:Wei Q; Zang L; Li YJ; Gu WJ; Jin N; Guo QH; Du J; Ba JM; Lyu ZH; Lu JM; Dou JT; Mu YM; Yang GQ
[Ad] Endereço:Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China.
[Ti] Título:[An analysis of four cases of misdiagnosed primary lymphocytic hypophysitis].
[So] Source:Zhonghua Nei Ke Za Zhi;56(7):512-515, 2017 Jul 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To improve the differential diagnosis of sellar region mass, 4 cases with sellar mass and misdiagnosed as lymphocytic hypophysitis (LYH) were reviewed retrospectively.The 4 patients (2 male and 2 female) aged 20-60 years old were all presented with symptoms of headache, polydipsia and polyuria.Biochemical studies confirmed the diagnoses of central diabetes insipidus and hypopituitarism.Head MRI scans showed LYH like image for all the cases, and, thus, high dose methylprednisolone pulse therapy (HDMPT) was applied to the patients.Their symptoms deteriorated and the sellar mass enlarged after a short period of partial improvement.Operations were performed in all the patients.Histology study showed craniopharyngioma with abscess, primary abscess, secondary hypophysitis caused by Wegener's granulomatosis, and germinoma with secondary hypophysitis, respectively.In conclusion, surgery or biopsy is necessary for those who presented with sellar region mass and was suspected to be with LYH, but with poor response or even worse after HDMPT.
[Mh] Termos MeSH primário: Diabetes Insípido/complicações
Germinoma/complicações
Hipofisite/complicações
Hipopituitarismo/etiologia
Imagem por Ressonância Magnética
Doenças da Hipófise/etiologia
[Mh] Termos MeSH secundário: Abscesso
Adulto
Biópsia
Feminino
Germinoma/patologia
Cefaleia
Seres Humanos
Hipofisite/diagnóstico
Hipopituitarismo/diagnóstico por imagem
Hipopituitarismo/patologia
Masculino
Meia-Idade
Doenças da Hipófise/diagnóstico por imagem
Doenças da Hipófise/patologia
Estudos Retrospectivos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2017.07.008


  7 / 3290 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28603206
[Au] Autor:Iwama S; Arima H
[Ad] Endereço:Research Center of Health, Physical Fitness and Sports, Nagoya University.
[Ti] Título:Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors.
[So] Source:Nihon Rinsho Meneki Gakkai Kaishi;40(2):90-94, 2017.
[Is] ISSN:1349-7413
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Immune checkpoint inhibitors, used for cancer immunotherapy, show anti-tumor effects through T cell activations. Monoclonal antibodies against cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death (PD)-1, or PD-ligand 1 which is a ligand of PD-1 have been shown to be effective in the treatments of advanced cancers including malignant melanoma, non-small cell lung cancer, and renal cell carcinoma. However, these drugs also have immune-related adverse events (irAEs). The irAEs, which have unique characteristics different from those seen in conventional cytotoxic anti-tumor medicines, are observed in the several tissues such as skin, gastrointestinal tract, liver, lung, muscle, nerve and endocrine systems. To safely use immune checkpoint inhibitors, it is quite important to understand the characteristics of irAEs and to manage them in clinical practice. In this review, we focus on clinical characteristics and pathogenesis of adverse events in the pituitary gland.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/efeitos adversos
Doenças da Hipófise/etiologia
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/uso terapêutico
Antígeno CTLA-4/imunologia
Seres Humanos
Hipofisite/etiologia
Hipofisite/terapia
Hipopituitarismo/epidemiologia
Hipopituitarismo/etiologia
Ipilimumab
Neoplasias/tratamento farmacológico
Doenças da Hipófise/terapia
Receptor de Morte Celular Programada 1/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (CTLA-4 Antigen); 0 (Ipilimumab); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor); 31YO63LBSN (nivolumab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE
[do] DOI:10.2177/jsci.40.90


  8 / 3290 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28566534
[Au] Autor:Andela CD; Repping-Wuts H; Stikkelbroeck NMML; Pronk MC; Tiemensma J; Hermus AR; Kaptein AA; Pereira AM; Kamminga NGA; Biermasz NR
[Ad] Endereço:Division of EndocrinologyDepartment of Medicine, and Centre for Endocrine Tumors (CETL), Leiden University Medical Centre, Leiden, The Netherlands c.d.andela@lumc.nl.
[Ti] Título:Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial.
[So] Source:Eur J Endocrinol;177(1):59-72, 2017 Jul.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Patients with pituitary disease report impairments in Quality of Life (QoL) despite optimal biomedical care. Until now, the effects of a self-management intervention (SMI) addressing psychological and social issues for these patients and their partners have not been studied. OBJECTIVE: To examine the effects of a SMI i.e. Patient and Partner Education Programme for Pituitary disease (PPEP-Pituitary). DESIGN AND SUBJECTS: A multicentre randomized controlled trial included 174 patients with pituitary disease, and 63 partners were allocated to either PPEP-Pituitary or a control group. PPEP-Pituitary included eight weekly sessions (90 min). Self-efficacy, bother and needs for support, illness perceptions, coping and QoL were assessed before the intervention (T0), directly after (T1) and after six months (T2). Mood was assessed before and after each session. RESULTS: Patients in PPEP-Pituitary reported improved mood after each session (except for session 1). In partners, mood only improved after the last three sessions. Patients reported higher self-efficacy at T1 ( = 0.016) which persisted up to T2 ( = 0.033), and less bother by mood problems directly after PPEP-Pituitary ( = 0.01), but more bother after six months ( = 0.001), although this increase was not different from baseline ( = 0.346). Partners in PPEP-Pituitary reported more vitality ( = 0.008) which persisted up to T2 ( = 0.034). At T2, partners also reported less anxiety and depressive symptoms ( ≤ 0.014). CONCLUSION: This first study evaluating the effects of a SMI targeting psychosocial issues in patients with pituitary disease and their partners demonstrated promising positive results. Future research should focus on the refinement and implementation of this SMI into clinical practice.
[Mh] Termos MeSH primário: Doenças da Hipófise/psicologia
Doenças da Hipófise/terapia
Autocuidado
Autoeficácia
[Mh] Termos MeSH secundário: Adaptação Psicológica
Adulto
Afeto
Idoso
Ansiedade/epidemiologia
Ansiedade/etiologia
Ansiedade/psicologia
Depressão/epidemiologia
Depressão/etiologia
Depressão/psicologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Doenças da Hipófise/complicações
Qualidade de Vida
Cônjuges/psicologia
Inquéritos e Questionários
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-16-1015


  9 / 3290 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28398895
[Au] Autor:Christou L; Thomas A; Dutta S; Shaw S; Jose B
[Ad] Endereço:Medical Student, Keele University Medical School, Keele.
[Ti] Título:Granulomatosis with polyangiitis presenting as a pituitary lesion.
[So] Source:Br J Hosp Med (Lond);78(4):234, 2017 Apr 02.
[Is] ISSN:1750-8460
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Granulomatose com Poliangiite/diagnóstico por imagem
Doenças da Hipófise/diagnóstico por imagem
[Mh] Termos MeSH secundário: Feminino
Granulomatose com Poliangiite/complicações
Seres Humanos
Hipogonadismo/etiologia
Hipotireoidismo/etiologia
Imagem por Ressonância Magnética
Meia-Idade
Doenças da Hipófise/complicações
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170615
[Lr] Data última revisão:
170615
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.12968/hmed.2017.78.4.234


  10 / 3290 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28351913
[Au] Autor:Webb SM; Crespo I; Santos A; Resmini E; Aulinas A; Valassi E
[Ad] Endereço:Hospital Sant PauIIB-Sant Pau, Research Center for Pituitary Diseases, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain swebb@santpau.cat.
[Ti] Título:MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease.
[So] Source:Eur J Endocrinol;177(1):R13-R26, 2017 Jul.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In the last few years, quality of life (QoL) has become an outcome measure in patients with pituitary diseases. OBJECTIVE: To describe the available data on QoL impairment evaluated with questionnaires in patients with pituitary diseases. DESIGN: Critical review of the pertinent literature and pragmatic discussion of available information. METHODS: Selection of relevant literature from PubMed and WOK, especially from the last 5 years and comprehensive analysis. RESULTS: QoL is impaired in all pituitary diseases, mostly in acromegaly and Cushing's disease (similar to other causes of Cushing's syndrome), but also in non-functioning pituitary adenomas and prolactinomas, especially in the active phase of the disease. Nevertheless, even after endocrine 'cure', scores tend to be below normative values, indicative of residual morbidity after hormonal control. The presence of hypopituitarism worsens subjective QoL perception, which can improve after optimal substitution therapy, including recombinant human growth hormone, when indicated. CONCLUSIONS: To improve the long-term outcome of pituitary patients, helping them to attain the best possible health, it appears desirable to include subjective aspects captured when evaluating QoL, so that the affected dimensions are identified and if relevant treated. Additionally, being aware that treatment outcome may not always mean complete normalisation of physical and mental issues related to QoL can be a first step to adaptation and conforming to this new status.
[Mh] Termos MeSH primário: Doenças da Hipófise/psicologia
Psicometria/métodos
Qualidade de Vida/psicologia
[Mh] Termos MeSH secundário: Seres Humanos
Doenças da Hipófise/terapia
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170330
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0041



página 1 de 329 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde